Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis
ConclusionSSc-ILD patients had significantly higher HRU, work loss, and direct and indirect costs compared to matched controls with neither SSc nor ILD.FundingBoehringer Ingelheim Pharmaceuticals, Inc.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Databases & Libraries | Drugs & Pharmacology | Emergency Medicine | Healthcare Costs | Insurance | Interstitial Lung Disease | Scleroderma | Study